Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.

INTRODUCTION: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ul...

Descripción completa

Detalles Bibliográficos
Autores: Marques-Pamies M, Gil J, Valassi E, Hernández M, Biagetti B, Giménez-Palop O, Martínez S, Carrato C, Pons L, Villar-Taibo R, Araujo-Castro M, Blanco C, Simón I, Simó-Servat A, Xifra G, Vázquez F, Pavón I, García-Centeno R, Zavala R, Hanzu FA, Mora M, Aulinas A, Vilarrasa N, Librizzi S, Calatayud M, de Miguel P, Alvarez-Escola C, Picó A, Sampedro M, Salinas I, Fajardo-Montañana C, Cámara R, Bernabéu I, Jordà M, Webb SM, Marazuela M, Puig-Domingo M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p9965
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones9965
https://www.frontiersin.org/articles/10.3389/fendo.2023.1269787/full
Access Level:acceso abierto
Palabra clave:acromegaly
acute octreotide test
individualized treatment
precision medicine
prediction
somatostatin analogs
id ES_fb8481ed48a13d3d3bf7fa74f53a51e7
oai_identifier_str oai:isabial.fundanetsuite.com:p9965
network_acronym_str ES
network_name_str España
repository_id_str
spelling Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.Marques-Pamies MGil JValassi EHernández MBiagetti BGiménez-Palop OMartínez SCarrato CPons LVillar-Taibo RAraujo-Castro MBlanco CSimón ISimó-Servat AXifra GVázquez FPavón IGarcía-Centeno RZavala RHanzu FAMora MAulinas AVilarrasa NLibrizzi SCalatayud Mde Miguel PAlvarez-Escola CPicó ASampedro MSalinas IFajardo-Montañana CCámara RBernabéu IJordà MWebb SMMarazuela MPuig-Domingo Macromegalyacute octreotide testindividualized treatmentprecision medicinepredictionsomatostatin analogsINTRODUCTION: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) . METHODS: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was =3SDS, were considered non-responders. The 2 hours GH value (GH(2h)) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. RESULTS: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 ± 4.2 vs 3.3 ± 2.1; p=0.01). CONCLUSION: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.FRONTIERS MEDIA SA2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones9965https://www.frontiersin.org/articles/10.3389/fendo.2023.1269787/fullFrontiers in EndocrinologyISSN: 16642392reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p99652026-06-12T10:20:37Z
dc.title.none.fl_str_mv Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
title Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
spellingShingle Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies M
acromegaly
acute octreotide test
individualized treatment
precision medicine
prediction
somatostatin analogs
title_short Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
title_full Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
title_fullStr Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
title_full_unstemmed Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
title_sort Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
dc.creator.none.fl_str_mv Marques-Pamies M
Gil J
Valassi E
Hernández M
Biagetti B
Giménez-Palop O
Martínez S
Carrato C
Pons L
Villar-Taibo R
Araujo-Castro M
Blanco C
Simón I
Simó-Servat A
Xifra G
Vázquez F
Pavón I
García-Centeno R
Zavala R
Hanzu FA
Mora M
Aulinas A
Vilarrasa N
Librizzi S
Calatayud M
de Miguel P
Alvarez-Escola C
Picó A
Sampedro M
Salinas I
Fajardo-Montañana C
Cámara R
Bernabéu I
Jordà M
Webb SM
Marazuela M
Puig-Domingo M
author Marques-Pamies M
author_facet Marques-Pamies M
Gil J
Valassi E
Hernández M
Biagetti B
Giménez-Palop O
Martínez S
Carrato C
Pons L
Villar-Taibo R
Araujo-Castro M
Blanco C
Simón I
Simó-Servat A
Xifra G
Vázquez F
Pavón I
García-Centeno R
Zavala R
Hanzu FA
Mora M
Aulinas A
Vilarrasa N
Librizzi S
Calatayud M
de Miguel P
Alvarez-Escola C
Picó A
Sampedro M
Salinas I
Fajardo-Montañana C
Cámara R
Bernabéu I
Jordà M
Webb SM
Marazuela M
Puig-Domingo M
author_role author
author2 Gil J
Valassi E
Hernández M
Biagetti B
Giménez-Palop O
Martínez S
Carrato C
Pons L
Villar-Taibo R
Araujo-Castro M
Blanco C
Simón I
Simó-Servat A
Xifra G
Vázquez F
Pavón I
García-Centeno R
Zavala R
Hanzu FA
Mora M
Aulinas A
Vilarrasa N
Librizzi S
Calatayud M
de Miguel P
Alvarez-Escola C
Picó A
Sampedro M
Salinas I
Fajardo-Montañana C
Cámara R
Bernabéu I
Jordà M
Webb SM
Marazuela M
Puig-Domingo M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acromegaly
acute octreotide test
individualized treatment
precision medicine
prediction
somatostatin analogs
topic acromegaly
acute octreotide test
individualized treatment
precision medicine
prediction
somatostatin analogs
description INTRODUCTION: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) . METHODS: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was =3SDS, were considered non-responders. The 2 hours GH value (GH(2h)) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. RESULTS: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 ± 4.2 vs 3.3 ± 2.1; p=0.01). CONCLUSION: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones9965
https://www.frontiersin.org/articles/10.3389/fendo.2023.1269787/full
url https://isabial.portalinvestigacion.com/publicaciones9965
https://www.frontiersin.org/articles/10.3389/fendo.2023.1269787/full
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Endocrinology
ISSN: 16642392
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425336189452288
score 15,812455

Similares en LA Referencia